Nosocomial bloodstream infections in United States hospitals: A three- year analysis

Clinical Infectious Diseases

Volumn 29, Issue 2, 1999, Pages 239-244

  Edmond, Michael B ^a,b   Wallace, Sarah E ^a,b   McClish, Donna K ^a,b   Pfaller, Michael A ^a,b   Jones, Ronald N ^a,b   Wenzel, Richard P ^a,b,c  

^a Division of Quality Health Care   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; METICILLIN; PIPERACILLIN; SULTAMICILLIN; TIMENTIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CANDIDIASIS; GEOGRAPHIC DISTRIBUTION; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; NONHUMAN; PRIORITY JOURNAL; UNITED STATES;

EID: 0032801225     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520192     Document Type: Article

References (21)

1. 1. National Center for Health Statistics. Monthly Vital Statistics Report 1995;43:5-7.
2. 2. Pittet D. Nosocomial bloodstream infections. In: Wenzel RP, ed. Prevention and control of nosocomial infections. 3rd ed. Baltimore: Williams and Wilkins, 1997:711-69.
3. 3. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598-601.
4. 4. Harrison PF, Lederberg J, eds. Antimicrobial resistance: issues and options: Institute of Medicine workshop report. Washington, DC: National Academy Press, 1998.
5. 5. Osterholm MT, Birkhead GS, Meriwether RA. Impediments to public health surveillance in the 1990s: the lack of resources and the need for priorities. Public Health Management Practice 1996;2:11-5.
6. 6. Wilke WW, Marshall SA, Coffman SL, et al. Vancomycin-resistant Enterococcus raffinosus: molecular epidemiology, species identification error, and frequency of occurrence in a national resistance surveillance program. Diagn Microbiol Infect Dis 1997;28:43-9.
7. 7. Jones RN, Marshall SA, Pfaller MA, et al. Nosocomial enterococcal blood stream infections in the SCOPE program: antimicrobial resistance, species occurrence, molecular testing results and laboratory testing accuracy. Diagn Microbiol Infect Dis 1997;29:95-102.
8. 8. Pfaller MA, Jones RN, Marshall SA, et al. Nosocomial streptococcal infections in the SCOPE program: species occurrence and antimicrobial resistance. Diagn Microbiol Infect Dis 1997;29:259-63.
9. 9. Marshall SA, Wilke WW, Pfaller MA, et al. Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE Program. Diagn Microbiol Infect Dis 1998;30:205-14.
10. 10. Pfaller MA, Jones RN, Marshall SA, et al. Inducible Amp C β-lactamase producing gram-negative bacilli from bloodstream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997;28:211-9.
11. 11. Jones RN, Pfaller MA, Marshall SA, et al. Antimicrobial activity of 12 broad-spectrum agents tested against 270 nosocomial blood stream infection isolates caused by non-enteric gram-negative bacilli: occurrence of resistance, molecular epidemiology, and screening for metalloenzymes. Diagn Microbiol Infect Dis 1997;29:187-92.
12. 12. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998;331:327-32.
13. 13. Pfaller MA, Jones RN, Messer SA, et al. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998;30:121-9.
14. 14. Pfaller MA, Lockhart, Pujol C, et al. Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. J Clin Microbiol 1998;36:1518-29.
15. 15. Ena J, Dick RW, Jones RN, et al. The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study. JAMA 1993;269:598-602.
16. 16. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997; 46:626-8, 635.
17. 17. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-6.
18. 18. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
19. 19. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep 1997;46:813-5.
20. 20. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-9.
21. 21. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994;170:1622-5.